Case report: Rapid clinical improvement in acute exacerbation of MuSK-MG with efgartigimod

作者全名：Zhu, Geke; Ma, Yongbo; Zhou, Han; Nie, Xiangtao; Qi, Wenjing; Hao, Lei; Guo, Xiuming

作者地址：[Zhu, Geke; Ma, Yongbo; Zhou, Han; Nie, Xiangtao; Qi, Wenjing; Hao, Lei; Guo, Xiuming] Chongqing Med Univ, Dept Neurol, Affiliated Hosp 1, Chongqing, Peoples R China

通信作者：Hao, L; Guo, XM (通讯作者)，Chongqing Med Univ, Dept Neurol, Affiliated Hosp 1, Chongqing, Peoples R China.

来源：FRONTIERS IN IMMUNOLOGY

ESI学科分类：IMMUNOLOGY

WOS号：WOS:001250818200001

JCR分区：Q1

影响因子：5.7

年份：2024

卷号：15

期号：　

开始页：　

结束页：　

文献类型：Article

关键词：myasthenia gravis; MuSK; exacerbation; lymphoplasmapheresis; efgartigimod

摘要：Myasthenia gravis with positive MuSK antibody often involves the bulbar muscles and is usually refractory to acetylcholinesterase inhibitors. For MuSK-MG patients who experience acute exacerbations and do not respond to conventional treatments, there is an urgent need to find more suitable treatment options. With the advent of biologic agents, efgartigimod has shown promising results in the treatment of MG. We report a 65-year-old MuSK-MG patient who presented with impaired eye movements initially, and the symptoms rapidly worsened within a week, affecting the limbs and neck muscles, and had difficulties in chewing and swallowing. Lymphoplasmapheresis did not achieve satisfactory results, but after a cycle of efgartigimod treatment, the patient's symptoms gradually improved and remained in a good clinical state for several months.

基金机构：Chongqing KingMed institute for clinical Laboratory; Zai Lab Limited

基金资助正文：We sincerely thank our patient and his family, and acknowledge the support of Chongqing KingMed institute for clinical Laboratory and Zai Lab Limited in this study.